# A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer

> **NCT00087620** · PHASE4 · TERMINATED · sponsor: **Hoffmann-La Roche**

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** XELODA [capecitabine]

## Key facts

- **NCT ID:** NCT00087620
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-09
- **Primary completion:** 2004-10
- **Final completion:** 2004-10
- **Target enrollment:** — (—)
- **Last updated:** 2017-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00087620

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00087620, "A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00087620. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*